IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy
Qin, Ya-Zhen1; Xu, Lan-Ping1; Chen, Huan1; Jiang, Qian1; Wang, Yu1; Jiang, Hao1; Zhang, Xiao-Hui1; Han, Wei1; Chen, Yu-Hong1; Wang, Feng-Rong1; Wang, Jing-Zhi1; Zhu, Hong-Hu1; Liu, Yan-Rong1; Jiang, Bin1; Liu, Kai-Yan1; Huang, Xiao-Jun1,2
关键词Clinical results myeloid leukemias and dysplasias prognostication
刊名LEUKEMIA & LYMPHOMA
2015-11-02
DOI10.3109/10428194.2015.1032964
56期:11页:3116-3123
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Hematology
研究领域[WOS]Oncology ; Hematology
关键词[WOS]MINIMAL RESIDUAL DISEASE ; POLYMERASE-CHAIN-REACTION ; FRENCH AML INTERGROUP ; QUANTITATIVE RT-PCR ; C-KIT MUTATIONS ; RISK STRATIFICATION ; PROGNOSTIC VALUE ; MARROW-TRANSPLANTATION ; CANCER PROGRAM ; GROUP-B
英文摘要

Eighty-six adult patients with inv(16) acute myeloid leukemia (AML) in first complete remission (CR1) were serially monitored for CBFB-MYH11 transcript levels during the early courses of chemotherapy. Fifty-seven and 29 of them received chemotherapy/autologous stem cell transplant (SCT) and allogeneic (allo-)SCT after second consolidation, respectively. For patients receiving chemotherapy/autologous SCT, the sole independent adverse prognostic factor for the cumulative incidence of relapse (CIR), disease-free survival (DFS) and overall survival (OS) was a CBFB-MYH11 level > 0.2% after course 2 consolidation (p = 0.003, 0.003 and 0.031), which was used to define a poor molecular response (MR). Allo-SCT significantly decreased the 3-year CIR and increased the DFS and OS of patients with a poor MR (p < 0.0001, 0.0001 and 0.045) but did not improve the outcome of patients with good MR (all p > 0.05) compared with chemotherapy/autologous SCT. Therefore, allo-SCT could improve the outcome of adult patients with inv(16) AML in CR1 with a poor MR during the early courses of chemotherapy.

语种英语
WOS记录号WOS:000365520200019
引用统计
被引频次:6[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63425
专题北京大学第二临床医学院_血液科
北京大学药学院_药事管理与临床药学系
医学人文研究院/公共教学部_哲学与社会科学系
作者单位1.Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
2.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Qin, Ya-Zhen,Xu, Lan-Ping,Chen, Huan,et al. Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy[J]. LEUKEMIA &amp; LYMPHOMA,2015,56(11):3116-3123.
APA Qin, Ya-Zhen.,Xu, Lan-Ping.,Chen, Huan.,Jiang, Qian.,Wang, Yu.,...&Huang, Xiao-Jun.(2015).Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy.LEUKEMIA & LYMPHOMA,56(11),3116-3123.
MLA Qin, Ya-Zhen,et al."Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy".LEUKEMIA & LYMPHOMA 56.11(2015):3116-3123.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Qin, Ya-Zhen]的文章
[Xu, Lan-Ping]的文章
[Chen, Huan]的文章
百度学术
百度学术中相似的文章
[Qin, Ya-Zhen]的文章
[Xu, Lan-Ping]的文章
[Chen, Huan]的文章
必应学术
必应学术中相似的文章
[Qin, Ya-Zhen]的文章
[Xu, Lan-Ping]的文章
[Chen, Huan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。